Investors Chronicle tips of week15 Mar 2018 18:48
Chi-Med is one of Investors Chronicle's Tips of the week in the issue out tomorrow. Below is just the summary. See a hard copy for the rest. I'm a subscriber so receive emails during the week.
With its plethora of near-term catalysts, excellent long-term outlook and strong financial position, Chi-Med is a rarity in the mid-sized biopharma world. Pre-tax profits may not be forecast until 2021, but the volume of clinical updates in the coming years, alongside the forecast growth in the Chinese commercial business, makes us confident that the share price will continue to climb. Buy.